Letter: risk of hepatocellular carcinoma in immune-tolerant phase of chronic hepatitis B
- PMID: 32852812
- DOI: 10.1111/apt.15966
Letter: risk of hepatocellular carcinoma in immune-tolerant phase of chronic hepatitis B
Comment in
-
Letter: risk of hepatocellular carcinoma in immune-tolerant phase of chronic hepatitis B-authors' reply.Aliment Pharmacol Ther. 2020 Sep;52(5):913-914. doi: 10.1111/apt.15992. Aliment Pharmacol Ther. 2020. PMID: 32852833 No abstract available.
Comment on
-
Extremely low risk of hepatocellular carcinoma development in patients with chronic hepatitis B in immune-tolerant phase.Aliment Pharmacol Ther. 2020 Jul;52(1):196-204. doi: 10.1111/apt.15741. Epub 2020 May 26. Aliment Pharmacol Ther. 2020. PMID: 32452564
References
REFERENCES
-
- Lee HA, Lee HW, Kim IH, et al. Extremely low risk of hepatocellular carcinoma development in patients with chronic hepatitis B in immune-tolerant phase. Aliment Pharmacol Ther. 2020;52:196-204.
-
- Liaw Y-F, Kao J-H, Piratvisuth T, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int. 2012;6:531-561.
-
- Terrault NA, Bzowej NH, Chang K-M, et al. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016;63:261-283.
-
- European Association for the Study of the Liver. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67:370-398.
-
- Liaw YF, Chu CM. Immune tolerance phase of chronic hepatitis B. Gastroenterology. 2017;152:1245-1246.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical